iSpecimen - רווח נקי למניה אחת בשנים עשר החודשים האחרונים ISPC

Rising demand for biomaterials for AI-driven drugs and the development of the iSpecimen (ISPC) marketplace are driving revenue, which is reflected in the YoY EPS dynamics on a rolling 12-month basis on GURU.Markets, where 86.70 represents the latest level. Long-term budgets from pharma behemoths ensure business resilience by minimizing cyclicality, while a diversified supplier network protects the company from the risks associated with owning biobanks.

This indicator measures the percentage change in rolling annual earnings per share, allowing for an assessment of capital generation efficiency and business scaling rates. By analyzing the YoY ttm growth of net income per share, an investor can see the impact of regulatory barriers and IT integration complexities at iSpecimen Inc. (ISPC), which determine the company's margin stability amidst stringent medical legislation.